Levetiracetam
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Levetiracetam (brand name Keppra) — Anticonvulsant; SV2A modulator.
Identification
- Therapeutic class: Anticonvulsant.
- Pharmacologic class: SV2A modulator.
Pharmacology
- Mechanism of action: Binds synaptic vesicle protein SV2A to reduce neurotransmitter release; favorable interaction profile.
- Onset / peak / duration: Rapid; PO, IV, and liquid available.
- Half-life / therapeutic level: Half-life 6 to 8 hours; level monitoring not routine.
Clinical use
- Indications: Focal, myoclonic, and tonic-clonic seizures; status epilepticus (IV).
- Usual dose, route, frequency: 500 to 1,500 mg PO or IV twice daily.
- Maximum dose / adjustments: Reduce in renal impairment.
Safety
- Contraindications: Hypersensitivity.
- Black box warning: None.
- Interactions: Minimal pharmacokinetic interactions.
- Pregnancy / lactation: Relatively preferred among antiepileptics; use if needed.
- High-alert: No.
Adverse effects
- Common side effects: Somnolence, dizziness, weakness.
- Serious effects to report: Behavioral and mood changes, irritability, depression, suicidal thoughts.
- Antidote / reversal: None; supportive care.
Nursing process
- Assessment before administration: Renal function, mood baseline, seizure baseline.
- Interventions during therapy: Screen mood and behavior.
- Monitor: Seizure frequency, renal function, mood.
- Evaluation / expected outcome: Seizure control.
Patient teaching
- Patient teaching: Report mood or behavior changes.
- Notify provider if: Depression, aggression, suicidal thoughts.
- Administration tips: With or without food; dose by renal function.